Comment from BioPhorum

Summary: BioPhorum, representing a group of 14 biopharmaceutical member organizations, supports the FDA's draft guidance on responding to Form 483 observations. They request specific clarifications to ensure the guidance is applied in a risk-based, proportionate manner that avoids unnecessary administrative burdens and clearly defines expectations within the 15-business-day response window.